At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
Ranolazine +1 moredrug
Likely dose
Ranolazine 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED)
In Brief
A Phase 4 clinical trial evaluating Ranolazine and Placebo for Microvascular Angina. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrovascular Angina
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartApr 2014
Primary CompletionNov 2015
TodayJul 2026
First PostedJan 31, 2014
Enrollment StartApr 1, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.4 years ago
Interventions
Ranolazinedrug
Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
Placebodrug